Catalyst Pharmaceutical Partners, Inc. Announces Completion Of Enrollment In Pivotal Phase 3 Trial Of Firdapse™ In Patients With Lambert-Eaton Myasthenic Syndrome

Published: Apr 01, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CORAL GABLES, Fla., April 1, 2014 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a specialty pharmaceutical company focused on developing safe and effective, approved medicines to treat orphan neuromuscular and neurological diseases, announced today that it has reached the patient enrollment target for its pivotal Phase 3 trial evaluating the safety and efficacy of Firdapse™ for the symptomatic treatment of Lambert-Eaton Myasthenic Syndrome (LEMS).

Help employers find you! Check out all the jobs and post your resume.

Back to news